
    
      This is a prospective, open-label, single-center trial including a single group of subjects
      with no known primary immunization history with TT or >10 years have passed since the last
      dose of tetanus containing vaccine was received. The study will enroll six subjects who would
      receive both dT and TIG concurrently on Day 1.

      All dosed subjects will be followed for 40 days during which Day 1, 2, 3, 4, 5, 7, 14, 21, 30
      and 40 time levels of tetanus antibodies will be measured in order to determine the serum
      level vs. time curve, Cmax, Tmax, and duration of protective antibody levels.
    
  